Mumbai, November 2014
— Q2FY15 Total Income at Rs. 761.16 crore, Y-o-Y growth 18 %
— Q2FY15 Net Profit at Rs. 50.72 crore, Y-o-Y growth of 20 %
— Board declares interim dividend of Rs. 2.25 per share
Editors’ Synopsis:
For the Quarter ended September 30, 2014:
For the Half Year ended September 30, 2014:
Aarti Industries Limited (AIL), a leading company in the field of chemical industry, today declared its financial results for the second quarter and half year ended September 30, 2014.
Total income for the quarter ended September 30, 2014 stood at Rs. 761.16 crore compared to Rs. 645.35 crore in Q2FY14, an increase of 17.9%.
Comparing on quarterly basis, net profit of the company increased by 19.8% to Rs. 50.72 crore in Q2FY15 as against Rs. 42.35 crore registered during Q2FY14.
EBIDTA increased by 15.05% to Rs. 121.98 crore for Q2FY15 from Rs. 106.02 crore in Q2FY14.
EPS for Q2FY15 stood at Rs. 5.72 as compared to Rs. 4.78 in Q2FY14 thereby registering a growth of 19.7 %.
The Board of Directors declared interim dividend of 45%, Rs. 2.25 per share (on the face value of Rs 5 each).
For the half year ended September 30, 2014, the Company’s total income stood at Rs. 1,500.93 crore as compared to Rs. 1,238.99 crore in half year ended September, 2013, an increase of 21.1 %.
Net profit for H1FY15 stood at Rs. 92.15 crore which is an increase of 42% from Rs. 64.88 crore in H1FY14.
EBIDTA increased by 28.9 % to Rs. 234.95 crore for H1FY15 from Rs. 182.26 crore in H1FY14.
EPS for H1FY15 stood at Rs. 10.40 as compared to Rs. 7.32 in H1FY14 thereby registering a growth of 42.10 %.
Commenting on the financial performance of the company Mr. Rajendra Gogri, Chairman and Managing Director, Aarti Industries Ltd, said, “ We are delighted to announce good set of numbers for yet another quarter. We have seen good growth in our pharma segment—both at topline and at EBIT level. ”
“ With our various expansion projects getting commissioned in coming period, going forward, we are expecting volume growth in all the three segments in second half. This should boost our topline as well as bottomline line in coming period ,” he added.
Pearson Syndrome is an extremely rare condition and the prevalence is approximately 1 in a…
A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…
People who smoke are also at much higher risk of developing diabetes compared to non-smokers…
17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…
Lonavala, November 12, 2024: As the global cancer burden rises to 30 million cases by…
The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…